Objectives: The objective of the present study was to compare the efficacy of cefuroxime with that of dicloxacillin as definitive antimicrobial therapy in methicillin-susceptible Staphylococcus aureus bacteraemia (MS-SAB) using a Danish bacteraemia database, information on the indication for antimicrobial therapy, multivariate adjustment and propensity score (PS) matching.
Introduction
The epidemiology of Staphylococcus aureus bacteraemia (SAB) has been extensively investigated, but evidence to guide antimicrobial therapy of SAB is still limited. 1 In Denmark, methicillin-susceptible S. aureus is considerably predominant over methicillin-resistant S. aureus 2 and the penicillinase-stable penicillin dicloxacillin is usually the first choice in SAB, followed by the second-generation cephalosporin cefuroxime. Whether these two antimicrobials are equally efficacious in SAB has not been determined. A randomized controlled trial would be the optimal, but very demanding and costly, way to compare the isoxazolylpenicillins with the cephalosporins. An alternative is to draw on existing data and apply optimal epidemiological tools.
A few retrospective studies of SAB have assessed outcome in relation to b-lactam group and found b-lactams other than penicillins to be associated with higher 30 day mortality. 3, 4 Retrospective cohort analyses of antimicrobial efficacy can be severely biased through 'confounding by indication' 5 as the choice of treatment remains a clinical judgement. Thus, patients with more severe infections, including severe sepsis or septic shock, are more prone to receiving broader antimicrobial coverage than patients in a better clinical condition despite a knowledge of the causative microorganism. Propensity score (PS) matching and multivariate adjustment are methods to reduce bias in analyses of retrospective treatment data. 6 The objective of this retrospective study was to compare the efficacy of cefuroxime with that of dicloxacillin as definitive antimicrobial therapy for methicillin-susceptible SAB (MS-SAB) using a Danish bacteraemia database, information on the indication for antimicrobial therapy, multivariate adjustment and PS matching.
Methods
Design, setting and ethics 
Microbiology
Hospitals in the greater Copenhagen area were served by departments of clinical microbiology (DCMs) at Copenhagen University Hospital, Hvidovre (DCM-Hvidovre) or Copenhagen University Hospital, Herlev (DCM-Herlev). In the North Denmark Region, the service was provided by the DCM at Aalborg University Hospital (DCM-Aalborg). Blood cultures were obtained when clinically indicated. Recommendations for culturing varied slightly among the three DCMs but were concordant in obtaining a minimum of 30 mL of blood per blood culture, either with two sets of two blood culture bottles or with one set comprising three or four bottles. The blood culture systems used were BACTEC TM (Becton Dickinson, Sparks, MD, USA) (DCM-Herlev) and BacT/ALERT (bioMérieux, Marcy l'Étoile, France) (DCM-Hvidovre and DCM-Aalborg).
Gram-positive cocci in clusters were routinely identified as S. aureus by a coagulase test (horse citrate plasma, SSI Diagnostica, Hillerød) or clumping factor (Slidex, bioMérieux). Antimicrobial susceptibility testing was performed at the DCMs with disc diffusion tests including cefoxitin according to EUCAST guidelines (www.EUCAST.org). The cloverleaf test 7 was used to confirm b-lactamase production if any doubt remained. All isolates were referred to the national reference laboratory at Statens Serum Institut, Copenhagen, for confirmation and further characterization. All data were recorded in a laboratory information system (ADBakt, Autonik, Ramsta, Sweden).
Data collection
Patients with MS-SAB were identified in the laboratory information system and their clinical data were retrieved from the patient records by one investigator (J. B. R.). Data included age, sex, antimicrobial therapy, the primary focus of infection, secondary manifestations, use of injection drugs, haemodialysis (HD), alcohol intake, smoking status and immunosuppressive medication. In order to assess confounding by indication, the physician's note detailing the indication to start empirical antimicrobial therapy was given special attention. Information on the patients' clinical condition and biochemistry within 2 days before and 1 day following the drawing of the first positive blood culture were recorded. Data on comorbidity and confirmation of the date of death were extracted from the National Patient Registry (NPR). 8 This registry is updated monthly and holds information on all hospital admissions and discharge diagnoses of all patients treated in Danish nonpsychiatric hospitals since 1 January 1977 as well as all outpatient contacts since 1 January 1995. Information obtained included date of admission, date of discharge and type of diagnosis (International Classification of Diseases, revision 10).
Variables and definitions
Hospital-acquired bacteraemia was defined as a positive blood culture obtained .48 h after admission, and community-onset bacteraemia was defined as a positive blood culture obtained within 48 h of admission. Patients who had been hospitalized within 30 days prior to the MS-SAB, or who visited the hospital regularly, for example for chemotherapy or HD, were considered to have healthcare-associated bacteraemia. 9 Polymicrobial bacteraemia was defined as the isolation of a separate microorganism from blood cultures within 2 days of the MS-SAB. Hospital specialties were classified as medical (including emergency, oncology/haematology, cardiology and neurology), surgical (including gynaecology and otorhino-laryngology) or intensive care. The Charlson Comorbidity Index (CCI) 10 was calculated by gathering diagnoses from the NPR 10 years prior to the episode of MS-SAB. Three comorbidity levels were defined: low (a score of 0), medium (1-2), and high (≥3). The Pitt bacteraemia score 11 is a severity of disease grading system that evaluates mental status, body temperature, blood pressure, mechanical ventilation and cardiac status for each patient within 2 days before and 1 day following the drawing of the first positive blood culture. A Pitt score ≥4 defined critical disease. One alcohol unit was defined as 12 g or 15 mL of pure alcohol. Alcohol abuse was defined as a known alcohol intake of .14 units for women and .21 units for men per week, and patients were considered to be smokers if they were recorded as such. Immunosuppressive medication was noted if treatment was ongoing with systemic glucocorticoids, calcineurin inhibitors, chemotherapeutic agents or biological therapy such as tumour necrosis factor-a inhibitors. The 30 day and 90 day allcause mortality defined outcomes.
Antimicrobial therapy
Adequate empirical antimicrobial therapy was defined as the intravenous (iv) administration of antimicrobials to which the S. aureus isolate was susceptible in vitro (an exception being made for an aminoglycoside if it was the only active antimicrobial administered to which the organism was susceptible) and had to be initiated within 1 day of obtaining the first positive blood culture. In cases of polybacteraemia, all bacterial isolates had to be susceptible to one or more of the antimicrobials administered empirically. Definitive antimicrobial therapy was assessed in patients surviving the day of the result of MS-SAB susceptibility testing and the definition was based on an 'intention-to-treat' principle, i.e. antimicrobial therapy being initiated or continued on the day of the MS-SAB susceptibility result. A b-lactam antimicrobial in combination with rifampicin, an aminoglycoside, fusidic acid or vancomycin was recorded as combination therapy. The total duration of adequate antimicrobial therapy from the start of empirical therapy to the end of definitive therapy was noted regardless of alterations in the type of administration, dosing or choice of antimicrobial agent.
Statistical analyses
All values in the text are given as medians (IQRs) unless otherwise specified. Categorical variables were compared by the x 2 test or Fisher's exact test as appropriate. Continuous variables were compared using the Kruskal-Wallis test or Wilcoxon rank-sum test. Univariate hazard ratios (HRs) and 95% CIs for 30 day and 90 day all-cause mortality were calculated with Cox proportional hazards regression analyses. Variables with a P value ,0.2 in the Treatment of methicillin-susceptible S. aureus bacteraemia 507 JAC univariate analyses were included in the multivariate analyses. Interaction terms were included in the analyses if indicated. A PS for the assignment of cefuroxime as definitive antimicrobial therapy was calculated using multivariate backward logistic regression. Variables relevant for the assignment of cefuroxime as definitive antimicrobial therapy and with no interaction were included; these were: age (continuous variable), CCI (continuous variable), HD, Pitt score (continuous variable), indication for empirical antimicrobial therapy, inadequate empirical antimicrobial therapy, the primary focus of infection, secondary manifestations, hospitals served by the DCMs, hospital specialties, acquisition of infection and the year of the MS-SAB episode (variables with P,0.2 remained in the final model). The greedy macro 12 was used to match patients treated definitively with dicloxacillin to patients treated with cefuroxime using the logit of the PS (LPS) with a caliper width equal to 0.2 of the standard deviation of LPS. 13 A P value ,0.05 was considered statistically significant. Data were analysed using SAS 9.2 (SAS Institute, Cary, NC, USA).
Results

MS-SAB cases
A total of 1006 patients with MS-SAB (aged ≥16 years) were identified ( Figure 1 ). Six isolates were considered to be contaminants, 29 patients did not receive antimicrobial therapy due to inevitable death or refusal of treatment, and 44 cases were excluded as they were recurrent episodes of MS-SAB.
Eighty patients did not survive the day of the MS-SAB susceptibility result and were excluded [death within 1 (1-2) day of the drawing of blood for culture]. Among these patients, 78.4% received adequate empirical antimicrobial therapy (cefuroxime: 60.8%; dicloxacillin: 5.4%; carbapenems: 5.4%; piperacillin/tazobactam: 2.7%; vancomycin: 2.7%; third-generation cephalosporins: 1.4%) and they differed significantly from the patients who were included (n¼ 756) (P,0.05) in terms of the following characteristics: they were older [age 80 (72 -85) years], they more frequently had polymicrobial bacteraemia (12.3%) and a respiratory focus (32.4%), and they had a higher Pitt score [6 (4 -8) Rasmussen et al. 
Indications for empirical antimicrobial therapy
A total of 28 different indications for empirical antimicrobial therapy were recorded among the 691 patients who received either dicloxacillin or cefuroxime as definitive antimicrobial therapy. Unknown indications were placed in one separate category, and all known indications were grouped into seven categories according to the attending physician's judgements of the suspected focus of infection and the severity of the disease. The eight categories: (i) 'unknown' (n¼82); (ii) 'infection alertness' (n¼120) (fever, positive blood culture, elevated infection-related biochemical markers, prophylaxis, acute surgery or endocarditis); (iii) 'iv device-related infection' (n¼31) (iv catheter infection or pacemaker infection); (iv) 'pneumonia' (n¼127); (v) 'skin/soft tissue/bone infection' (n¼91) (subcutaneous abscess, erysipelas, bursitis, decubitus ulcer, post-operative infection, discitis, osteomyelitis or purulent arthritis); (vi) 'urinary tract infection' (n¼61); (vii) 'severe infection' (n¼155) (sepsis with an unknown focus, severe sepsis/septic shock, urosepsis, meningitis, haemolytic-uraemic syndrome or febrile neutropenia); and (viii) 'other indication' (n¼24) (tonsillitis, parotitis, abdominal focus or epididymitis).
Characteristics of patients treated definitively with either dicloxacillin or cefuroxime
Adequate empirical antimicrobial therapy was given to fewer patients in the dicloxacillin group (cefuroxime: 43.5%; dicloxacillin: 21.7%; other antimicrobials: 21.7%) compared with the cefuroxime group (cefuroxime: 70.0%; dicloxacillin: 0.3%; other antimicrobials: 24.2%) (P¼0.0009). Within 3 days, definitive antimicrobial therapy was started among 87.8% of the patients in the dicloxacillin group and 94.4% in the cefuroxime group (P¼0.0024). Antimicrobial therapy lasting ≥14 days was more frequent among patients given dicloxacillin as definitive antimicrobial therapy (76.4%) compared with cefuroxime (65.0%) (P¼0.001). The patients who received dicloxacillin also differed significantly (P,0.05) from those who were treated with cefuroxime in terms of the following characteristics (Table 1) : empirical antimicrobial therapy was less frequently given for indications of 'severe infection', they had a lower Pitt score and a higher frequency of HD, they were less frequently admitted to intensive care and to hospitals served by DCM-Hvidovre, there was more frequently a skin/soft tissue/bone primary focus and endocarditis was more frequently seen as a secondary manifestation.
PS for assignment of cefuroxime as definitive antimicrobial therapy
Independent variables relevant to the assignment of cefuroxime as definitive antimicrobial therapy were identified by multivariate backward logistic regression (Table S1, 
Mortality
The overall 30 day and 90 day mortality among all the patients included (n¼ 756) was 20.5% (155/756) and 31.3% (237/756), respectively. There was no statistically significant difference in 30 day mortality between definitive antimicrobial therapy with cefuroxime compared with dicloxacillin in the crude data (22.9% versus 17.1%, P ¼0.057) ( Table 1 ) or in a PS-adjusted multivariate analysis: HR 1.43 (95% CI 1.03 -1.98) (P ¼ 0.93) ( Tables 2 and 3 ). Age (per year increment), Pitt score (per unit increment) and hospitalacquired infection were all independently associated with increased risk of death within 30 days (P, 0.05).
By crude analysis, 90 day mortality was higher for patients receiving cefuroxime as definitive antimicrobial therapy compared with dicloxacillin (37.5% versus 24.7%, P ¼ 0.0003) ( Table 1 and Figure 2 ), corresponding to an unadjusted HR of 1.63 (95% CI 1.25-2.14). Furthermore, definitive antimicrobial therapy with cefuroxime remained associated with increased 90 day mortality in the PS-adjusted multivariate analysis (Tables 3 and 4) (HR 1.43, 95% CI 1.03 -1.98). An interaction was found between combination therapy and the acquisition of bacteraemia, so an interaction term was included in the analysis. The following variables were also independently associated with increased 90 day mortality: age (per year increment), Pitt score (per unit increment), a respiratory focus, ongoing treatment with immunosuppressive medication and 'iv device-related infection', 'other indication' and 'severe infection' among the eight categories of indications for empirical antimicrobial therapy. Rasmussen et al.
PS matching
Patients with similar characteristics treated definitively with dicloxacillin were matched with patients treated with cefuroxime using the PS. A total of 187 patients from each group were matched (Table 5 ). There were no statistically significant differences in any observed characteristics between the matched patients, including the total duration of antimicrobial therapy [dicloxacillin group, 17 (13 -27) days versus the cefuroxime group, 16 (11 -29) days (P ¼0.17)]. The two groups had a similar 30 day mortality (P ¼ 1.00), but the matched patients treated definitively with cefuroxime had a higher 90 day mortality (36.9% versus 26.2%, P¼ 0.026), corresponding to an OR of 1.65 (95% CI 1.06-2.56).
Sensitivity analyses
Empirical antimicrobial therapy with cefuroxime was not statistically associated with a higher risk of death compared with dicloxacillin in a PS-adjusted multivariate analyses that also included patients who did not survive the day of the MS-SAB susceptibility result: 30 day mortality, HR 0.78 (95% CI 0.46 -1.33), and 90 day mortality, HR 1.03 (95% CI 0.64-1.65). Definitive antimicrobial therapy with cefuroxime remained statistically associated with increased 90 day mortality in an analysis adjusted for the total duration of antimicrobial therapy (HR 1.41, 1.01-1.96). In subgroup PS-adjusted multivariate analyses for 90 day mortality, patients treated definitively with cefuroxime had a statistically higher risk of death among patients with CCI≥3 (HR 1.68, 95% CI 1.03 -2.74), age ≤65 years (HR 3.02, 95% CI 1.38-6.62) and a respiratory/unknown primary focus (HR 1.72, 95% CI 1.08 -2.72). There Treatment of methicillin-susceptible S. aureus bacteraemia 511 JAC was no statistically significant difference in 90 day mortality among patients with CCI ,3, age .65 years, a subgroup of primary foci other than unknown/respiratory focus, or stratification for Pitt score ≥4. 'Immortal time bias' 14 was assessed in patients who survived a minimum of 4 days from when the first positive blood culture was obtained. Among these patients, definitive antimicrobial therapy with cefuroxime remained significantly associated with increased 90 day mortality compared with dicloxacillin in the PS matching (OR 1.73, 95% CI 1.11-2.68) and PS-adjusted multivariate analysis (HR 1.42, 95% CI 1.02 -1.98).
Discussion
The key findings of this study were a non-significant difference in 30 day mortality and a statistically significant increase in 90 day mortality among patients with MS-SAB who received cefuroxime as definitive antimicrobial therapy compared with dicloxacillin. The results were consistent in the PS matching and PS-adjusted multivariate analyses. Moreover, the study was multicentre based and we had access to detailed information from patient charts and longterm follow-up on all the patients included. Nevertheless, the two groups were different in terms of several observed characteristics, and even though we used PS and adjusted for indications for empirical antimicrobial therapy, there may still have been unmeasured confounders of importance to the outcome, including MS-SAB management issues (the use of echocardiography and follow-up blood cultures, the timely removal of intravascular devices, surgical revision of the primary focus, etc.) and social deprivation in the greater Copenhagen area. Hence, residual confounding may explain the statistically significant difference in mortality only with a 90 day follow-up period. Another reason for the finding could be the relatively small sample size and therefore the occurrence of a statistical type II error. A third option is that a term longer than 1 month is necessary to assess the true impact of bacteraemia on morbidity and mortality. Sequelae from vital organ dysfunction following severe infection and interaction of infection with underlying diseases have previously been proposed to become manifest after a period longer than 1 month. 15 Our results differed from those of two recent retrospective studies. Nissen et al. 3 found that definitive antimicrobial monotherapy with penicillin or dicloxacillin was associated with a lower 30 day mortality than monotherapy with cefuroxime among patients with penicillin-susceptible SAB. The study had a smaller sample size, did not assess the indications for antimicrobial therapy or test for immortality bias and defined antimicrobial therapy differently from this study. Paul et al. 4 did not find any significant difference in 90 day mortality when comparing various b-lactams as definitive antimicrobial therapy for MS-SAB. The authors did not include patients who died within the first week or who received inadequate empirical antimicrobial therapy, but they did include recurrent cases with an interval of 1 year between episodes. If we excluded all who died during the first week, we were also unable to find any difference in 90 day mortality between cefuroxime or dicloxacillin as definitive antimicrobial therapy (data not shown).
To our knowledge, the present study is the first to use treatment indications in the analysis of retrospective data. Antimicrobial therapy prescribed for indications of 'severe infection' predicted a 2-fold risk of death within 90 days compared with 'infection alertness' and demonstrates that indications for treatment can be independently associated with outcome. The indication categories 'iv device-related infection' and 'other indication' were also independently associated with increased 90 day mortality. This could be because permanent iv catheters are associated with high comorbidity, such as disseminated malignancy, and symptoms of an abdominal infection can be severe and may signal underlying critical disease.
The retrospective design caused additional limitations. We did not consider dosing or the duration of antimicrobial therapy with dicloxacillin or cefuroxime in the inclusion criteria. However, doing so could have increased the risk of selection bias, and Rasmussen et al. conditions for the assessment of antimicrobial therapy were similar for all the patients included. The focus of infection may have been inappropriately assigned as the extent of diagnostic procedures differed among the patients. In conclusion, the present study found that definitive antimicrobial therapy with dicloxacillin led to a better outcome than therapy with cefuroxime among patients with MS-SAB. Due to the retrospective design and limitations of the study, the results should be considered to be preliminary. A randomized controlled trial is needed to verify our findings.
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